Compare GUT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GUT | DCTH |
|---|---|---|
| Founded | 1999 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.5M | 578.4M |
| IPO Year | 1999 | 2015 |
| Metric | GUT | DCTH |
|---|---|---|
| Price | $5.19 | $14.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | ★ 281.8K | 251.9K |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.61 |
| Revenue Next Year | N/A | $24.27 |
| P/E Ratio | ★ N/A | $368.38 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.03 | $8.12 |
| 52 Week High | $7.07 | $17.42 |
| Indicator | GUT | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 27.11 | 39.08 |
| Support Level | N/A | $14.26 |
| Resistance Level | $6.26 | $16.51 |
| Average True Range (ATR) | 0.20 | 0.51 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 11.54 | 17.28 |
Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.